Welcome to our dedicated page for AtriCure SEC filings (Ticker: ATRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AtriCure's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AtriCure's regulatory disclosures and financial reporting.
Nachman Shlomo reported acquisition or exercise transactions in this Form 4 filing.
AtriCure director Nachman Shlomo received a grant of 6,144 shares of AtriCure, Inc. common stock as a Restricted Stock Award under the company’s 2023 Stock Incentive Plan. The award was granted at no cash cost and will fully vest on the one-year anniversary of the grant date. Following this equity grant, Shlomo directly owns 24,655 shares of AtriCure common stock.
AtriCure, Inc. director Kristine B. Johnson reported receiving a grant of common stock as equity compensation. She acquired 6,144 shares of Common Stock on May 18, 2026 at a stated price of $0.00 per share under the AtriCure, Inc. 2023 Stock Incentive Plan.
The award is structured as a Restricted Stock Award, with all 6,144 shares scheduled to vest on the one-year anniversary of the grant date. Following this grant, Johnson directly holds a total of 55,954 shares of AtriCure common stock, reflecting her updated ownership position as reported.
GROVES REGINA E reported acquisition or exercise transactions in this Form 4 filing.
AtriCure, Inc. director Regina E. Groves received a grant of 6,144 shares of Common Stock as a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The footnote states these shares will vest on the one-year anniversary of the grant date. After this equity award, Groves directly holds 39,859 shares of AtriCure common stock.
WEHRWEIN SVEN reported acquisition or exercise transactions in this Form 4 filing.
AtriCure, Inc. director Sven Wehrwein received a grant of 6,144 shares of common stock as equity compensation. The award was made at a price of $0.00 per share under the AtriCure, Inc. 2023 Stock Incentive Plan and is structured as a Restricted Stock Award. According to the terms, these shares will vest on the one-year anniversary of the grant date. Following this grant, Wehrwein directly holds a total of 40,518 shares of AtriCure common stock.
WHITE ROBERT S. reported acquisition or exercise transactions in this Form 4 filing.
AtriCure, Inc. director Robert S. White received a grant of 6,144 shares of common stock as a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The award has no purchase price and will vest in full on the one-year anniversary of the grant date.
After this grant, White directly holds a total of 128,318 shares of AtriCure common stock, reflecting routine equity-based compensation rather than an open-market purchase or sale.
AtriCure, Inc. reported results of its 2026 Annual Meeting of Stockholders, where stockholders approved amendments to key equity compensation plans and all other management proposals. The 2023 Stock Incentive Plan share pool was raised from 4,500,000 to 6,000,000 shares of common stock, expanding capacity for future equity awards.
Stockholders also approved adding 750,000 shares to the 2018 Employee Stock Purchase Plan, ratified Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026, re-elected nine directors for one-year terms, and supported executive compensation in an advisory say-on-pay vote.
AtriCure, Inc. Chief Scientific Officer Doraiswamy Vinayak sold 5,000 shares of common stock in an open-market transaction at a price of $28.13 per share. After this sale on May 15, he directly holds 91,875 AtriCure common shares.
Company ATRC submitted a Form 144 disclosing proposed and recent sales of common stock. The filing lists planned dispositions of performance shares and restricted stock granted 03/01/2024 totaling specific lots of 3,162, 181, 1,237 and 420 shares. The filing also reports a sale by Vinayak Doraiswamy of 5,000 shares on 03/12/2026 for $149,151.50.
The intermediary named is Morgan Stanley Smith Barney LLC Executive Financial Services located at 1 New York Plaza; the record includes a reference date of 05/15/2026 and a NASDAQ listing. The disclosure lists each security type and grant date; timing and methods for the planned dispositions are those reported on the form.
AtriCure, Inc. disclosure: Wellington Management Group LLP and related Wellington entities filed Amendment No. 1 to a Schedule 13G/A reporting beneficial ownership of 3,382,555 shares of AtriCure common stock, equal to 6.79% of the class. The filing states these shares are owned of record by clients of Wellington investment advisers and that voting and dispositive powers are shared among the listed Wellington entities.